SE0001151D0 - Method for producing a controlled-release composition - Google Patents
Method for producing a controlled-release compositionInfo
- Publication number
- SE0001151D0 SE0001151D0 SE0001151A SE0001151A SE0001151D0 SE 0001151 D0 SE0001151 D0 SE 0001151D0 SE 0001151 A SE0001151 A SE 0001151A SE 0001151 A SE0001151 A SE 0001151A SE 0001151 D0 SE0001151 D0 SE 0001151D0
- Authority
- SE
- Sweden
- Prior art keywords
- controlled
- producing
- pore
- release composition
- forming agent
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 abstract 1
- 229930010555 Inosine Natural products 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- 229960005261 aspartic acid Drugs 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 229960003624 creatine Drugs 0.000 abstract 1
- 239000006046 creatine Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 229960002989 glutamic acid Drugs 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 229960003786 inosine Drugs 0.000 abstract 1
- 235000016337 monopotassium tartrate Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 abstract 1
- 229940081543 potassium bitartrate Drugs 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 229920003176 water-insoluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0001151A SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Method for producing a controlled-release composition |
| JP2001572081A JP4963767B2 (ja) | 2000-03-31 | 2001-03-23 | 制御放出性製剤の製法 |
| AU2001239658A AU2001239658A1 (en) | 2000-03-31 | 2001-03-23 | Method for producing a controlled-release preparation |
| EP01914312A EP1267842B1 (de) | 2000-03-31 | 2001-03-23 | Verfahren zur herstellung eines tabletts mit kontrollierter freisetzung mit der verwendung von einem porenbildenden agens in der beschichtung |
| PCT/SE2001/000626 WO2001074336A1 (en) | 2000-03-31 | 2001-03-23 | Method for producing a controlled-release preparation |
| EP04025989A EP1516616A1 (de) | 2000-03-31 | 2001-03-23 | Eine kontrollierte Freigabezusammensetzung mit spezifischen Poren-Bildnern im Filmüberzug |
| DE60106889T DE60106889T2 (de) | 2000-03-31 | 2001-03-23 | Verfahren zur herstellung eines tabletts mit kontrollierter freisetzung mit der verwendung von einem porenbildenden agens in der beschichtung |
| AT01914312T ATE281156T1 (de) | 2000-03-31 | 2001-03-23 | Verfahren zur herstellung eines tabletts mit kontrollierter freisetzung mit der verwendung von einem porenbildenden agens in der beschichtung |
| US09/819,813 US6974591B2 (en) | 2000-03-31 | 2001-03-29 | Method for producing a controlled-release preparation |
| US11/255,073 US20060159755A1 (en) | 2000-03-31 | 2005-10-19 | Method for producing a controlled release preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0001151A SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Method for producing a controlled-release composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0001151D0 true SE0001151D0 (sv) | 2000-03-31 |
Family
ID=20279094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0001151A SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Method for producing a controlled-release composition |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6974591B2 (de) |
| EP (2) | EP1516616A1 (de) |
| JP (1) | JP4963767B2 (de) |
| AT (1) | ATE281156T1 (de) |
| AU (1) | AU2001239658A1 (de) |
| DE (1) | DE60106889T2 (de) |
| SE (1) | SE0001151D0 (de) |
| WO (1) | WO2001074336A1 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6551617B1 (en) * | 2000-04-20 | 2003-04-22 | Bristol-Myers Squibb Company | Taste masking coating composition |
| CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| US20030175349A1 (en) * | 2001-01-30 | 2003-09-18 | Council Of Scientific And Industrial Research | Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient |
| US6960357B2 (en) | 2001-05-25 | 2005-11-01 | Mistral Pharma Inc. | Chemical delivery device |
| US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| KR20120034211A (ko) * | 2002-09-20 | 2012-04-10 | 안드렉스 랩스 엘엘씨 | 약제학적 정제 |
| US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| GB0518579D0 (en) * | 2005-09-12 | 2005-10-19 | Cr Technologies Llp | Controlled delivery creatine formulations and method of using the same |
| RU2408368C2 (ru) | 2005-06-27 | 2011-01-10 | Биовэйл Лэборэториз Интернэшнл С.Р.Л. | Препараты соли бупропиона с модифицированным высвобождением |
| ATE536867T1 (de) | 2006-03-16 | 2011-12-15 | Tris Pharma Inc | Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen |
| TW200815045A (en) * | 2006-06-29 | 2008-04-01 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of ropinirole and methods of use thereof |
| DE102006030860A1 (de) * | 2006-07-04 | 2008-01-10 | Universität Regensburg | Oligomere von Isonitril-Metallkomplexen als Triplett-Emitter für OLED-Anwendungen |
| CN101766581B (zh) * | 2008-12-30 | 2012-08-15 | 北京科信必成医药科技发展有限公司 | 一种群孔释放的盐酸地尔硫卓择时控释片及其制备方法 |
| RU2559083C9 (ru) | 2009-05-19 | 2016-01-20 | Неуродерм Лтд | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
| WO2011041414A1 (en) | 2009-09-30 | 2011-04-07 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
| US8623409B1 (en) | 2010-10-20 | 2014-01-07 | Tris Pharma Inc. | Clonidine formulation |
| CN110123743A (zh) | 2010-11-15 | 2019-08-16 | 纽罗德姆有限公司 | L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用 |
| EP2481411A1 (de) * | 2011-01-27 | 2012-08-01 | Ratiopharm GmbH | Orale Dosierformen für modifizierte Freisetzung mit dem JAK3-Hemmer tasocitinib |
| WO2013183055A1 (en) | 2012-06-05 | 2013-12-12 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| WO2014011830A1 (en) | 2012-07-12 | 2014-01-16 | Mallinckrodt Llc | Extended release, abuse deterrent pharmaceutical compositions |
| AU2013302657B2 (en) | 2012-08-15 | 2018-08-09 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| EP3116475B1 (de) | 2014-03-13 | 2020-11-04 | Neuroderm Ltd | Dopa-decarboxylasehemmerzusammensetzungen |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| WO2020128062A1 (en) * | 2018-12-21 | 2020-06-25 | Re-Vana Therapeutics Ltd | Ocular compositions |
| WO2021171972A1 (ja) * | 2020-02-28 | 2021-09-02 | 株式会社Screenホールディングス | 固体製剤 |
| US11918689B1 (en) | 2020-07-28 | 2024-03-05 | Tris Pharma Inc | Liquid clonidine extended release composition |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USB587055I5 (de) * | 1956-05-24 | |||
| US4557925A (en) | 1982-07-08 | 1985-12-10 | Ab Ferrosan | Membrane-coated sustained-release tablets and method |
| US4629619A (en) * | 1984-09-05 | 1986-12-16 | Ab Ferrosan | Membrane-coated sustained-release tablets and method |
| SE8803822D0 (sv) * | 1988-10-26 | 1988-10-26 | Novel dosage form | |
| US5376383A (en) | 1988-11-21 | 1994-12-27 | Merck & Co., Inc. | Method for enhancing the lowering of plasma-cholesterol levels |
| US5126146A (en) * | 1989-10-23 | 1992-06-30 | Merck & Co., Inc. | Cellulosic coating |
| US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5324351A (en) * | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
| US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
| US6207190B1 (en) * | 1998-08-13 | 2001-03-27 | Chronorx, Llc | Dosage forms for the treatment of the chronic glaucomas |
-
2000
- 2000-03-31 SE SE0001151A patent/SE0001151D0/xx unknown
-
2001
- 2001-03-23 WO PCT/SE2001/000626 patent/WO2001074336A1/en not_active Ceased
- 2001-03-23 AU AU2001239658A patent/AU2001239658A1/en not_active Abandoned
- 2001-03-23 EP EP04025989A patent/EP1516616A1/de not_active Withdrawn
- 2001-03-23 DE DE60106889T patent/DE60106889T2/de not_active Expired - Lifetime
- 2001-03-23 JP JP2001572081A patent/JP4963767B2/ja not_active Expired - Fee Related
- 2001-03-23 AT AT01914312T patent/ATE281156T1/de not_active IP Right Cessation
- 2001-03-23 EP EP01914312A patent/EP1267842B1/de not_active Expired - Lifetime
- 2001-03-29 US US09/819,813 patent/US6974591B2/en not_active Expired - Fee Related
-
2005
- 2005-10-19 US US11/255,073 patent/US20060159755A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4963767B2 (ja) | 2012-06-27 |
| WO2001074336A1 (en) | 2001-10-11 |
| ATE281156T1 (de) | 2004-11-15 |
| EP1267842A1 (de) | 2003-01-02 |
| DE60106889D1 (de) | 2004-12-09 |
| US20060159755A1 (en) | 2006-07-20 |
| AU2001239658A1 (en) | 2001-10-15 |
| EP1516616A1 (de) | 2005-03-23 |
| DE60106889T2 (de) | 2006-03-23 |
| JP2003528910A (ja) | 2003-09-30 |
| EP1267842B1 (de) | 2004-11-03 |
| US20010038853A1 (en) | 2001-11-08 |
| US6974591B2 (en) | 2005-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001239658A1 (en) | Method for producing a controlled-release preparation | |
| DE69331948D1 (de) | Angenehm schmeckende pharmazeutische zusammensetzungen | |
| DE69933689D1 (de) | Verfahren zur herstellung von oralen calcium zusammensetzungen | |
| ATE288259T1 (de) | Verfahren zur herstellung fester oraler darreichungsformen mit retardierender wirkstofffreisetzung | |
| DE60034565D1 (de) | Verfahren zur herstellung eines umhüllten geschmackmaskierten granulats mit sofortiger wirkstofffreisetzung | |
| DK0652747T3 (da) | Morfinpræparat med reguleret frigivelse | |
| DE50110049D1 (de) | Magnesium-ammonium-phosphat-zemente, deren herstellung und verwendung | |
| ATE380022T1 (de) | Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen | |
| DE60136858D1 (de) | Copolymer vom polycarbonsäure typ, verfahren zu seiner herstellung, zementadditiv und zementzusammensetzung | |
| ZA200500716B (en) | Solid pharmaceutical composition containing a lipophilic active principle and preparation method thereof | |
| EE04700B1 (et) | Segamisest sõltumatud toimeainet aeglustatult vabastavad mitmeosalised ravimvormid ja nende valmistamismeetodid | |
| DE60108255D1 (de) | Clarithromycin enthaltende zubereitung mit verlängerter freisetzung | |
| EP0377517A3 (de) | Theophyllin-Dosisform | |
| CY1107559T1 (el) | Μικροκοκκοι θειικης μορφινης, μεθοδος παρασκευης και φαρμακευτικα σκευασματα | |
| ATE198152T1 (de) | Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe | |
| ATE327737T1 (de) | Verfahren zur herstellung von arzneistoffgranulatkörnern, die arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische zubereitungen | |
| HUP0000141A2 (hu) | Eljárás legfeljebb 90 tömeg% gyógyhatású anyagot tartalmazó pelletek előállítására | |
| DE69616072D1 (de) | Stabile feste formulierung eines enalaprilsalzes und verfahren zu deren herstellung | |
| DE60042972D1 (de) | Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung | |
| KR960021061A (ko) | 경구 투여용 약제학적 조성물 | |
| EA199900205A1 (ru) | Лекарственные формы для перорального введения, содержащие бета-лактамный антибиотик | |
| EP0616802A4 (de) | Orale zubereitung zur freisetzung im unteren verdauungstract. | |
| EP1258254A4 (de) | Zusammensetzungen zur verzögerten abgabe von physiologisch aktiven verbindungen die kaum wasserlösslich sind, verfahren zu deren herstellung und deren verwendung | |
| DE69901062D1 (de) | Multipartikuläre pharmazeutische form mit gesteuerter und gepulster wirkstoffabgabe und verfahren zu deren herstellung | |
| ATE531360T1 (de) | Mikrokügelchen mit verzögerter freisetzung und verfahren zu ihrer herstellung |